EARLY ACADEMIC PURSUITS:
Linxi Zhu commenced her academic journey at Nanjing University, where she pursued a Bachelor's degree from July 2015 to June 2020. Following her undergraduate studies, she continued her academic pursuit at the same institution, earning a Master's degree from July 2020 to June 2021. Linxi Zhu then advanced further in her educational journey, undertaking a Ph.D. program at Nanjing University from July 2021 to June 2023.
PROFESSIONAL ENDEAVORS:
Since September 2023, Linxi Zhu has been serving as a Surgeon at Nanjing Drum Tower Hospital, marking a significant transition from academic pursuits to practical application in the field of surgery.
CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS :
Linxi Zhu's research has made notable contributions to the field of cancer genetics. Notably, her work titled "Loss of Claudin-1 incurred by DNMT aberration promotes pancreatic cancer progression" (published in Cancer Lett., 2024) sheds light on the molecular mechanisms underlying pancreatic cancer progression. Additionally, she has contributed to the development and validation of a nomogram for predicting post-operative abdominal infection in patients undergoing pancreaticoduodenectomy, as well as exploring the role of preoperative biliary drainage in postoperative outcomes after pancreaticoduodenectomy.
IMPACT AND INFLUENCE:
Zhu's research impact extends beyond pancreatic cancer, with contributions to the field of intrahepatic cholangiocarcinoma. Her collaborative work on high endothelial venule as a prognostic immune-related biomarker in patients with resected intrahepatic cholangiocarcinoma (published in Cell Prolif., 2023) underscores her diverse research interests.
ACADEMIC CITES:
Linxi Zhu has published in reputable journals, evident from her publications in Cancer Lett., Clin Chim Acta, Gland Surg, Cell Prolif., and Front Oncol. The citations received for her work demonstrate its scholarly significance and recognition within the academic community.
LEGACY AND FUTURE CONTRIBUTIONS:
Zhu's legacy lies in her comprehensive understanding of pancreatic cancer and related surgical interventions. Her research on individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer showcases innovative approaches. Looking forward, Linxi Zhu is poised to contribute further to the field, leaving a lasting impact on surgical and oncological research.
NOTABLE PUBLICATIONS
Development and validation of a nomogram for predicting post-operative abdominal infection in patients undergoing pancreaticoduodenectomy. 2022
Loss of Claudin-1 incurred by DNMT aberration promotes pancreatic cancer progression. 2024